Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $7.3 million.

  • Kezar Life Sciences' Shares Outstanding (Diluted Average) rose 36.85% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 36.85%. This contributed to the annual value of $7.3 million for FY2024, which is 48.07% up from last year.
  • Latest data reveals that Kezar Life Sciences reported Shares Outstanding (Diluted Average) of $7.3 million as of Q3 2025, which was up 36.85% from $7.3 million recorded in Q2 2025.
  • Kezar Life Sciences' Shares Outstanding (Diluted Average)'s 5-year high stood at $72.5 million during Q2 2023, with a 5-year trough of $6.7 million in Q4 2022.
  • For the 5-year period, Kezar Life Sciences' Shares Outstanding (Diluted Average) averaged around $31.7 million, with its median value being $7.3 million (2025).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 3862.81% in 2022, then plummeted by 8994.7% in 2024.
  • Over the past 5 years, Kezar Life Sciences' Shares Outstanding (Diluted Average) (Quarter) stood at $52.8 million in 2021, then crashed by 87.23% to $6.7 million in 2022, then grew by 7.7% to $7.3 million in 2023, then rose by 0.48% to $7.3 million in 2024, then increased by 0.45% to $7.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $7.3 million for Q3 2025, versus $7.3 million for Q2 2025 and $7.3 million for Q1 2025.